Semaglutide Market (2026-2031) - Rising Obesity and Type 2 Diabetes Prevalence Drives Growth
Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Semaglutide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Global Semaglutide Market to Reach USD 58.72 Billion by 2031, Growing at 12.93% CAGR
The global semaglutide market was valued at USD 27.84 billion in 2025 and is projected to increase from USD 31.97 billion in 2026 to USD 58.72 billion by 2031. This represents a compound annual growth rate of 12.93% during the 2026-2031 forecast period. Rising obesity and type 2 diabetes prevalence, expanded cardiovascular indications, and growing demand for convenient treatment options are supporting market growth.
Obesity and Type 2 Diabetes Drive Semaglutide Demand
More than 1 billion adults worldwide were living with obesity in 2024, while approximately 537 million people had diabetes. This expanding disease burden is increasing demand for therapies that support glycemic control, chronic weight management, and cardiovascular risk reduction.
Policy developments are also improving access. Several Middle Eastern health ministries added GLP-1 receptor agonists to essential medicines lists in 2025. In Asia-Pacific, earlier onset of diabetes is creating additional treatment demand, with China reporting that 35% of new diagnoses occur among adults younger than 45. Once-weekly administration continues to appeal to working-age patients and may support stronger treatment adherence.
Clinical Efficacy Supports Continued Adoption
Semaglutide's demonstrated weight-loss and cardiovascular outcomes remain central to its market position. Wegovy achieved mean weight loss of 15.8% in the STEP 1 trial. European health technology assessment organizations also updated cost-effectiveness models in 2025 to account for cardiovascular benefits, strengthening the case for semaglutide in secondary prevention.
Expanded regulatory approvals for cardiovascular risk reduction and the growing adoption of self-injectable pens and oral tablets are expected to create additional growth opportunities. Higher-dose oral semaglutide formulations under clinical evaluation could further increase adoption among patients who prefer tablets over injections.
High Treatment Costs and Reimbursement Barriers Limit Access
Despite strong demand, affordability remains a significant market restraint. Semaglutide ranked among the most expensive chronic obesity treatments in 2025, with monthly costs reaching approximately USD 1,300 in some markets. Brazil, Mexico, South Africa, and Turkey declined reimbursement after budget-impact assessments indicated that semaglutide could account for 5% to 8% of pharmaceutical spending.
Patients in high-income countries also face access challenges, including prior-authorization delays averaging six weeks. Tiered pricing and patient-assistance programs have not yet substantially increased adoption in price-sensitive markets. Manufacturing constraints involving pen-fill and cartridge capacity may create further supply pressure as global demand rises.
Ozempic Leads While Wegovy Records Rapid Growth
Ozempic accounted for 65.31% of the semaglutide market by brand in 2025. Its market leadership reflects its earlier launch and inclusion in cardiometabolic treatment guidelines following the SUSTAIN-6 study, which reported a 26% reduction in cardiovascular events.
Wegovy is forecast to expand at a 15.13% CAGR through 2031 as broader indications support increased reimbursement and patient eligibility. Rybelsus continues to serve patients who prefer oral treatment and could gain market share if higher-dose formulations receive regulatory approval.
Injectable pens generated 59.73% of market revenue in 2025 and are projected to grow at a 16.87% CAGR. Once-weekly dosing has supported 72% adherence at 12 months. Oral tablets represent the remaining formulation share and are positioned for stronger adoption in primary care if ongoing late-stage studies confirm the efficacy of 25 mg and 50 mg doses.
North America Maintains Market Leadership
North America generated 46.38% of global semaglutide revenue in 2025. Market leadership is supported by employer-sponsored coverage, Medicare Part D coverage for diabetes, and expanding cardiovascular indications. U.S. adult obesity prevalence reached 41.9% in 2024, sustaining substantial treatment demand. Canada expanded access following the addition of a cardiovascular indication, while limited public reimbursement continues to moderate growth in Mexico.
Europe presents varied reimbursement conditions. Germany recognized additional cardiovascular prevention benefits in 2025, while the United Kingdom recommended semaglutide for eligible adults with established cardiovascular disease. Spain completed formulary inclusion in late 2025, although France and Italy continue to evaluate real-world evidence and budget implications.
Asia-Pacific Emerges as the Fastest-Growing Region
Asia-Pacific is projected to record the highest regional CAGR at 17.12%. China approved semaglutide for obesity in late 2024 and is targeting essential-medicine reimbursement in 2026. Japan's anticipated cardiovascular approval and South Korea's December 2025 label extension are expected to expand access further.
India remains primarily a self-pay market, although future biosimilar development may improve affordability after relevant patent expirations. Australia reimburses Wegovy through the Pharmaceutical Benefits Scheme but maintains strict prior-authorization requirements. The Middle East, Africa, and South America are also expected to achieve double-digit growth as insurance coverage, reimbursement policies, and urban private demand evolve.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Obesity & Type-2 Diabetes
4.2.2 Superior Weight-Loss Efficacy Versus Other GLP-1 RAs
4.2.3 Expanded Regulatory Approvals for CVD Risk Reduction
4.2.4 Growing Adoption of Self-Injectable Pens & Oral Tablets
4.2.5 Employer-Sponsored Obesity-Management Programs
4.2.6 API Supply-Chain Localization Incentives in Asia
4.3 Market Restraints
4.3.1 High Therapy Cost & Limited Reimbursement
4.3.2 Supply Shortages of Pen-Fill & Cartridge Capacity
4.3.3 GI Side-Effects Driving Real-World Discontinuations
4.3.4 Regulatory Scrutiny of Off-Label Cosmetic Use
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Brand
5.1.1 Wegovy
5.1.2 Ozempic
5.1.3 Rybelsus
5.2 By Formulation
5.2.1 Injectable
5.2.2 Oral
5.3 By Indication
5.3.1 Type-2 Diabetes
5.3.2 Chronic Weight Management
5.3.3 Cardiovascular Risk Reduction
5.3.4 Others
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 Novo Nordisk A/S
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/qm45xd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.